Tenderwize
Wróć do wyszukiwania

Ranibizumab

AOK Bremen/Bremerhaven·Bremen, Germany·Deadline Nov 04, 2027 · 436 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Verträge 2025-4

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

58 / 100

Czynniki ryzyka

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Open-house supply contracts for pharmaceutical products / active substances under § 130a Abs. 8 SGB V.
  • Ranibizumab lot: contract access for the named active substance, excluding medicines on the BfArM children's medicines list.
Pokaż pełne podsumowanie

Open-house supply arrangement for pharmaceutical products in Germany, led by AOK Bremen/Bremerhaven. The notice states that interested pharmaceutical companies may join on equal terms, with no exclusivity and no individual negotiations. One lot is identified for Ranibizumab (ATC S01LA04). The notice contains a major inconsistency: the structured data says the contract runs until 31.12.2027, while the XML notice for the lot states 31.12.2025 and the XML notice text also mentions 31.05.2027 / 01.06.2025. Because of this, deadline and duration should be verified before bidding.

Ryzyka

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only pharmaceutical undertakings within the meaning of § 4 Abs. 18 AMG may conclude the rebate contract for the offered medicines.

Certifications

  • For bidders established outside Germany, proof of registration in a comparable register from the home country must be provided in a certified German translation.

Administrative

  • The buyer requests self-declarations on reliability and delivery capability, and a self-declaration on Russia sanctions.

Zamawiający

Lokalizacja

Bremen, DEU

Identyfikator

DE114397726

Działalność

Health

Części (1)

LOT-0001

Ranibizumab

Supply/open-house contract for Ranibizumab (ATC S01LA04) under § 130a Abs. 8 SGB V. The lot excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children's medicines). Interested pharmaceutical companies or groups of companies may join under identical conditions; no exclusivity and no individual negotiations are stated. The lot is based on notice text and structured data.

SuppliesEU fundedElectronic submission

Lokalizacja

Germany

Kategoria

Pharmaceutical products

Termin

Expired Dec 31, 2025

Szczegóły zamówienia

Data publikacji
04 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
730881-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3